Works by Pricop, Luminita

Results: 28

Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.

Published in:

Rheumatology & Therapy, 2024, v. 11, n. 3, p. 675, doi. 10.1007/s40744-024-00666-1

By:

Kivitz, Alan J.;
Kremer, Joel M.;
Legerton III, Clarence W.;
Pricop, Luminita;
Singhal, Atul

Publication type:

Article

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.

Published in:

Rheumatology & Therapy, 2019, v. 6, n. 3, p. 393, doi. 10.1007/s40744-019-0163-5

By:

Kivitz, Alan J.;
Nash, Peter;
Tahir, Hasan;
Everding, Andrea;
Mann, Heřman;
Kaszuba, Andrzej;
Pellet, Pascale;
Widmer, Albert;
Pricop, Luminita;
Abrams, Ken

Publication type:

Article

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.

Published in:

Arthritis & Rheumatology, 2016, v. 68, n. 8, p. 1914, doi. 10.1002/art.39685

By:

van der Heijde, Désirée;
Landewé, Robert B.;
Mease, Philip J.;
McInnes, Iain B.;
Conaghan, Philip G.;
Pricop, Luminita;
Ligozio, Greg;
Richards, Hanno B.;
Mpofu, Shephard

Publication type:

Article

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis.

Published in:

Arthritis Research & Therapy, 2022, v. 24, n. 1, p. 1, doi. 10.1186/s13075-022-02944-1

By:

Mease, Philip;
van der Heijde, Désirée;
Kirkham, Bruce;
Schett, Georg;
Orbai, Ana-Maria;
Ritchlin, Christopher;
Merola, Joseph F.;
Pricop, Luminita;
James, David A.;
Zhu, Xuan;
Ligozio, Gregory

Publication type:

Article

Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus.

Published in:

Human Genetics, 2005, v. 117, n. 2/3, p. 220, doi. 10.1007/s00439-005-1302-3

By:

Blank, Marissa C.;
Stefanescu, Radu N.;
Masuda, Emi;
Marti, Francesc;
King, Philip D.;
Redecha, Patricia B.;
Wurzburger, Robert J.;
Peterson, Margaret G. E.;
Tanaka, Shizuko;
Pricop, Luminita

Publication type:

Article

Correlation of F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2013, v. 40, n. 3, p. 403, doi. 10.1007/s00259-012-2282-x

By:

Roivainen, Anne;
Hautaniemi, Sannamari;
Möttönen, Timo;
Nuutila, Pirjo;
Oikonen, Vesa;
Parkkola, Riitta;
Pricop, Luminita;
Ress, Rudyard;
Seneca, Nicholas;
Seppänen, Marko;
Yli-Kerttula, Timo

Publication type:

Article

Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study.

Published in:

Arthritis & Rheumatology, 2025, v. 77, n. 2, p. 171, doi. 10.1002/art.42997

By:

Kivitz, Alan;
Sedova, Liliana;
Churchill, Melvin;
Kotha, Roshan;
Singhal, Atul;
Torres, Alexander;
Valenzuela, Guillermo;
Whelan, Sarah;
Dumortier, Thomas;
Zhu, Xuan;
Martin, Ruvie;
Pricop, Luminita

Publication type:

Article

Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.

Published in:

2020

By:

Orbai, Ana-Maria;
McInnes, Iain B.;
Coates, Laura C.;
Husni, M. Elaine;
Gladman, Dafna D.;
Gossec, Laure;
Pricop, Luminita;
Chambenoit, Olivier;
Xiangyi Meng;
Mease, Philip J.;
Meng, Xiangyi

Publication type:

journal article

Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.

Published in:

2020

By:

Deodhar, Atul;
Gladman, Dafna D.;
McInnes, Iain B.;
Spindeldreher, Sebastian;
Martin, Ruvie;
Pricop, Luminita;
Porter, Brian;
Safi Jr., Jorge;
Shete, Abhijit;
Bruin, Gerard;
Safi, Jorge Jr

Publication type:

journal article

Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.

Published in:

Arthritis Care & Research, 2017, v. 69, n. 3, p. 347, doi. 10.1002/acr.23111

By:

Kavanaugh, Arthur;
Mease, Philip J.;
Reimold, Andreas M.;
Tahir, Hasan;
Rech, Jürgen;
Hall, Stephen;
Geusens, Piet;
Wang, Zailong;
Pricop, Luminita;
Mpofu, Shephard

Publication type:

Article

Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.

Published in:

2016

By:

Kavanaugh, Arthur;
Mease, Philip J;
Reimold, Andreas M;
Tahir, Hasan;
Rech, Jürgen;
Hall, Stephen;
Geusens, Piet;
Wang, Zailong;
Pricop, Luminita;
Mpofu, Shephard;
FUTURE-1 Study Group

Publication type:

journal article

Repertoires of Antigen Receptors in Tdt Congenitally Deficient Mice.

Published in:

International Reviews of Immunology, 1996, v. 13, n. 4, p. 317, doi. 10.3109/08830189609061755

By:

Komori, Toshihisa;
Pricop, Luminita;
Hatakeyama, Akira;
Bona, Constantin A.;
Alt, Frederick W.

Publication type:

Article

Study of Self Reactive Antibodies in Kappa-Light Chain Deficient Mice.

Published in:

Autoimmunity, 1995, v. 20, n. 2, p. 113, doi. 10.3109/08916939509001935

By:

Hatakeyama, Akira;
Pricop, Luminita;
Swamy, Kuppu;
Kasturi, N.;
Bona, Constantin A.

Publication type:

Article

Antibody response against poly (Glu.

Published in:

European Journal of Immunology, 1995, v. 25, n. 4, p. 1039, doi. 10.1002/eji.1830250427

By:

Pricop, Luminita;
Hatakeyama, Akira;
Moran, Tom;
Bona, Constantin

Publication type:

Article

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.

Published in:

Arthritis Research & Therapy, 2018, v. 20, n. 1, p. N.PAG, doi. 10.1186/s13075-018-1610-3

By:

McInnes, Iain B.;
Mease, Philip J.;
Schett, Georg;
Kirkham, Bruce;
Strand, Vibeke;
Williams, Nicole;
Fox, Todd;
Pricop, Luminita;
Jugl, Steffen M.;
Gandhi, Kunal K.;
on behalf of the FUTURE 2 Study Group

Publication type:

Article

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

Published in:

Arthritis Research & Therapy, 2018, v. 20, p. 1, doi. 10.1186/s13075-018-1551-x

By:

Nash, Peter;
Mease, Philip J.;
McInnes, Iain B.;
Rahman, Proton;
Ritchlin, Christopher T.;
Blanco, Ricardo;
Dokoupilova, Eva;
Andersson, Mats;
Kajekar, Radhika;
Mpofu, Shephard;
Pricop, Luminita;
on behalf of the FUTURE 3 study group

Publication type:

Article

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.

Published in:

Arthritis Research & Therapy, 2017, v. 19, p. 1, doi. 10.1186/s13075-017-1490-y

By:

Pavelka, Karel;
Kivitz, Alan;
Dokoupilova, Eva;
Blanco, Ricardo;
Maradiaga, Marco;
Tahir, Hasan;
Pricop, Luminita;
Andersson, Mats;
Readie, Aimee;
Porter, Brian

Publication type:

Article

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study.

Published in:

ACR Open Rheumatology, 2020, v. 2, n. 1, p. 18, doi. 10.1002/acr2.11097

By:

Mease, Philip J.;
Kavanaugh, Arthur;
Reimold, Andreas;
Tahir, Hasan;
Rech, Juergen;
Hall, Stephen;
Geusens, Piet;
Pellet, Pascale;
Delicha, Eumorphia Maria;
Pricop, Luminita;
Mpofu, Shephard

Publication type:

Article

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.

Published in:

Acta Dermato-Venereologica, 2022, v. 102, p. 1, doi. 10.2340/actadv.v102.563

By:

GOTTLIEB, Alice B.;
DEODHAR, Atul;
MCINNES, Iain B.;
BARALIAKOS, Xenofon;
REICH, Kristian;
SCHREIBER, Stefan;
Weibin BAO;
MARFO, Kwaku;
RICHARDS, Hanno B.;
PRICOP, Luminita;
SHETE, Abhijit;
TRIVEDI, Vivek;
KEEFE, Deborah;
PAPAVASSILIS, Charis C.;
JAGIELLO, Piotr;
PAPANASTASIOU, Philemon;
MEASE, Philip J.;
LEBWOHL, Mark

Publication type:

Article

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.

Published in:

Rheumatology, 2020, v. 59, n. 6, p. 1325, doi. 10.1093/rheumatology/kez420

By:

Heijde, Désirée van der;
Mease, Philip J;
Landewé, Robert B M;
Rahman, Proton;
Tahir, Hasan;
Singhal, Atul;
Boettcher, Elke;
Navarra, Sandra;
Zhu, Xuan;
Ligozio, Gregory;
Readie, Aimee;
Mpofu, Shephard;
Pricop, Luminita

Publication type:

Article

263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period.

Published in:

2019

By:

McInnes, Iain B;
Deodhar, Atul;
Gladman, Dafna D;
Ren, Mengyuan;
Spindeldreher, Sebastian;
Pricop, Luminita;
Porter, Brian;
Safi, Jorge;
Shete, Abhijit;
Bruin, Gerard

Publication type:

Abstract

258 Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial.

Published in:

2019

By:

Tahir, Hasan;
Mease, Philip J;
Kavanaugh, Arthur;
Reimold, Andreas;
Rech, Jürgen;
Hall, Stephen;
Geusens, Piet;
Pellet, Pascale;
Delicha, Eumorphia Maria;
Pricop, Luminita;
Mpofu, Shephard

Publication type:

Abstract

257 Secukinumab demonstrates a consistent safety profile with up to 5 years' treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses.

Published in:

2019

By:

McInnes, Iain B;
Mease, Philip J;
Reich, Kristian;
Nash, Peter;
Widmer, Albert;
Abrams, Ken;
Pricop, Luminita;
Fox, Todd

Publication type:

Abstract

256 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study.

Published in:

2019

By:

McInnes, Iain B;
Kirkham, Bruce;
Nash, Peter;
Rahman, Proton;
Gottlieb, Alice B;
Ding, Kevin;
Pricop, Luminita

Publication type:

Abstract

254 Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from FUTURE 2 AND FUTURE 3 Phase 3 studies.

Published in:

2019

By:

McInnes, Iain B;
Wallman, Johan K;
Schett, Georg;
Quebe-Fehling, Erhard;
Rasouliyan, Lawrence;
Pricop, Luminita;
Fasth, Andreas E;
Gaillez, Corine

Publication type:

Abstract

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

Published in:

Rheumatology, 2017, v. 56, n. 11, p. 1993, doi. 10.1093/rheumatology/kex301

By:

McInnes, Iain B.;
Mease, Philip J.;
Ritchlin, Christopher T.;
Rahman, Proton;
Gottlieb, Alice B.;
Kirkham, Bruce;
Kajekar, Radhika;
Delicha, Eumorphia-Maria;
Pricop, Luminita;
Mpofu, Shephard

Publication type:

Article

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.

Published in:

Arthritis Research & Therapy, 2019, v. 21, n. 1, p. N.PAG, doi. 10.1186/s13075-019-2055-z

By:

Coates, Laura C.;
Wallman, Johan K.;
McGonagle, Dennis;
Schett, Georg A.;
McInnes, Iain B.;
Mease, Philip J.;
Rasouliyan, Lawrence;
Quebe-Fehling, Erhard;
Asquith, Darren L.;
Fasth, Andreas E. R.;
Pricop, Luminita;
Gaillez, Corine

Publication type:

Article

Sequential knockoffs for continuous and categorical predictors: With application to a large psoriatic arthritis clinical trial pool.

Published in:

2021

By:

Kormaksson, Matthias;
Kelly, Luke J.;
Zhu, Xuan;
Haemmerle, Sibylle;
Pricop, Luminita;
Ohlssen, David

Publication type:

journal article